Physician profile
John W Thompson, JR.
NPI 1871594663
$813.19
in general payments reported to CMS, 2019-2025
20 companies · $87.73 in 2025
The $87.73 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $116 · 2021: $83.86 · 2022: $16.24 · 2023: $68.26 · 2024: $17.98 · 2025: $87.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $169.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $96.37 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $64.29 | 2019-2021 | |
| Abiomed | $63.90 | 2025 | |
| Boston Scientific Corporation | $57.24 | 2019 | |
| Insmed, INC. | $50.93 | 2020-2022 | |
| Pfizer INC. | $35.40 | 2019 | |
| Mallinckrodt Enterprises LLC | $34.20 | 2019 | |
| Abbvie INC. | $29.95 | 2021 | |
| Genentech USA, INC. | $26.96 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $24.09 | 2019 | |
| Philips North America LLC | $23.83 | 2025 | Vest Therapy Und |
| Genzyme Corporation | $22.15 | 2019 | |
| Livanova USA, INC. | $20.64 | 2023 | Lifesparc |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2024 | Glassia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.66 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.35 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.01 | 2019 | |
| Inari Medical, INC. | $14.91 | 2019 | |
| Allergan, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.